These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 16908348)

  • 1. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients.
    Roé E; García Muret MP; Marcuello E; Capdevila J; Pallarés C; Alomar A
    J Am Acad Dermatol; 2006 Sep; 55(3):429-37. PubMed ID: 16908348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
    Bragg J; Pomeranz MK
    Dermatol Online J; 2007 Jan; 13(1):1. PubMed ID: 17511934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cutaneous side effects of EGFR inhibitors--appearance and management].
    Wollenberg A; Kroth J; Hauschild A; Dirschka T
    Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients.
    de Noronha e Menezes NM; Lima R; Moreira A; Varela P; Barroso A; Baptista A; Parente B
    Eur J Dermatol; 2009; 19(3):248-51. PubMed ID: 19258241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cutaneous side effects of EGF-receptor inhibition and their management].
    Gutzmer R; Werfel T; Kapp A; Elsner J
    Hautarzt; 2006 Jun; 57(6):509-13. PubMed ID: 16205868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
    Ocvirk J; Cencelj S
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
    Wu PA; Balagula Y; Lacouture ME; Anadkat MJ
    Curr Opin Oncol; 2011 Jul; 23(4):343-51. PubMed ID: 21537180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
    Santoro F; Cozzani E; Parodi A
    J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse cutaneous reactions to epidermal growth factor receptor inhibitors: a study of 14 patients.
    Santiago F; Gonçalo M; Reis JP; Figueiredo A
    An Bras Dermatol; 2011; 86(3):483-90. PubMed ID: 21738965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
    Segaert S; Tabernero J; Chosidow O; Dirschka T; Elsner J; Mancini L; Maughan T; Morere JF; Santoro A; Sobrero A; Van Cutsem E; Layton A
    J Dtsch Dermatol Ges; 2005 Aug; 3(8):599-606. PubMed ID: 16033478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective.
    Lacouture ME; Melosky BL
    Skin Therapy Lett; 2007; 12(6):1-5. PubMed ID: 17762902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: a case series and a literature review of therapeutic approaches.
    Nikolaou V; Stratigos A; Antoniou C; Kiagia M; Nikolaou C; Katsambas A; Syrigos K
    Dermatology; 2010; 220(3):243-8. PubMed ID: 20110632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cutaneous side effects of EGF receptor inhibitors].
    Nassar D; Soutou B; Aractingi S
    Bull Cancer; 2009 Dec; 96 Suppl():S85-91. PubMed ID: 20034874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two cases of acneiform eruption induced by inhibitor of epidermal growth factor receptor.
    Gencoglan G; Ceylan C
    Skin Pharmacol Physiol; 2007; 20(5):260-2. PubMed ID: 17641540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR-targeted therapy and related skin toxicity.
    Morse L; Calarese P
    Semin Oncol Nurs; 2006 Aug; 22(3):152-62. PubMed ID: 16893744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
    Mitchell EP; Perez-Soler R; Van Cutsem E; Lacouture ME
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):4-9. PubMed ID: 18154212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cutaneous toxicity associated with cetuximab treatment in metastatic colorectal cancer].
    Rodríguez-Murphy E; Villanueva-Herraiz S; Ortega-García MP; Pérez-Feliu A; López-Montenegro Soria MA; Camps-Herrero C
    Farm Hosp; 2011; 35(3):114-20. PubMed ID: 21497124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.
    Ong CK; Tan WC; Chan LC; Abdul Razak M
    Med J Malaysia; 2012 Apr; 67(2):222-3. PubMed ID: 22822651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.
    Amitay-Laish I; David M; Stemmer SM
    Oncologist; 2010; 15(9):1002-8. PubMed ID: 20709888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
    Eames T; Landthaler M; Karrer S
    Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.